Anbio Biotechnology
NNNN
$6.57
$0.192.98%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 91.19% | 91.19% | -35.96% | -35.96% | -82.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.19% | 91.19% | -35.96% | -35.96% | -82.85% |
| Cost of Revenue | 53.57% | 53.57% | -36.90% | -36.90% | -83.54% |
| Gross Profit | 117.62% | 117.62% | -34.66% | -34.66% | -82.33% |
| SG&A Expenses | -50.88% | -50.88% | -58.84% | -58.84% | 5,119.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.40% | 37.40% | -45.11% | -45.11% | -78.66% |
| Operating Income | 153.19% | 153.19% | 1,555.21% | 1,555.21% | -86.02% |
| Income Before Tax | 136.53% | 136.53% | 91,725.00% | 91,725.00% | -84.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 136.53% | 136.53% | 91,725.00% | 91,725.00% | -84.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 136.53% | 136.53% | 91,725.00% | 91,725.00% | -84.81% |
| EBIT | 153.19% | 153.19% | 1,555.21% | 1,555.21% | -86.02% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 701.89% | 701.89% | -- | -- | -- |
| Normalized Basic EPS | 706.06% | 706.06% | -- | -- | -- |
| EPS Diluted | 701.89% | 701.89% | -- | -- | -- |
| Normalized Diluted EPS | 706.06% | 706.06% | -- | -- | -- |
| Average Basic Shares Outstanding | -70.28% | -70.28% | -- | -- | -- |
| Average Diluted Shares Outstanding | -70.28% | -70.28% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |